EPS for Aclaris Therapeutics, Inc. (ACRS) Expected At $-0.95

July 14, 2018 - By Jenna Rose

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Logo

Analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report $-0.95 EPS on August, 14.They anticipate $0.39 EPS change or 69.64 % from last quarter’s $-0.56 EPS. After having $-0.98 EPS previously, Aclaris Therapeutics, Inc.’s analysts see -3.06 % EPS growth. The stock increased 0.78% or $0.16 during the last trading session, reaching $20.59. About 153,757 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 24.32% since July 14, 2017 and is downtrending. It has underperformed by 36.89% the S&P500.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $636.36 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

More notable recent Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news were published by: Nasdaq.com which released: “Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on July 03, 2018, also Seekingalpha.com with their article: “Aclaris Therapeutics expands leadership team” published on June 15, 2018, Nasdaq.com published: “FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia …” on July 09, 2018. More interesting news about Aclaris Therapeutics, Inc. (NASDAQ:ACRS) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus” published on June 30, 2018 as well as Nasdaq.com‘s news article titled: “Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in …” with publication date: June 28, 2018.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.